

Contents

List of Contributors XIII

Preface XVII

Part One Medicinal Chemistry 1

- 1 **Organometallic Complexes as Enzyme Inhibitors: A Conceptual Overview** 3
Philipp Anstaett and Gilles Gasser
 - 1.1 Introduction 3
 - 1.2 Organometallic Compounds as Inert Structural Scaffolds for Enzyme Inhibition 3
 - 1.3 Organometallic Compounds Targeting Specific Protein Residues 11
 - 1.4 The Bioisosteric Substitution 14
 - 1.5 Novel Mechanisms of Enzyme Inhibition with Organometallic Compounds 19
 - 1.6 Organometallic Compounds as Cargo Delivers of Enzyme Inhibitors 25
 - 1.7 Organometallic Enzyme Inhibitors for Theranostic Purposes 30
 - 1.8 Conclusion 34

Acknowledgments 35
Abbreviations 35
References 36
- 2 **The Biological Target Potential of Organometallic Steroids** 43
Gérard Jaouen, Siden Top, and Michael J. McGlinchey
 - 2.1 Introductory Note on Nuclear Receptors 43
 - 2.1.1 Early History 43
 - 2.1.2 Primary Structure of Nuclear Receptors 44
 - 2.1.3 Estrogen Receptors 45
 - 2.1.4 Androgens 45
 - 2.1.5 Glucocorticoids 46
 - 2.1.6 Progesterone and Progestogens 46

2.1.7	Mineralocorticoids and Aldosterone	46
2.1.8	Selective Modulators of Nuclear Receptors	47
2.1.8.1	Selective Estrogen Receptor Modulators (SERMs)	47
2.1.8.2	Selective Androgen Receptor Modulators (SARMs)	48
2.1.8.3	Selective Progesterone Receptor Modulators (SPRMs)	48
2.1.9	Mechanism of Action of Nuclear Receptors	48
2.1.10	Endocrine Disruptors	50
2.2	Steroids and Organometallics: An Overview of the Transitional Period from the Use of Organometallics in Synthesis to the Emergence of Bioorganometallics	53
2.2.1	Early Examples of Organometallic Estradiol Derivatives with Biological Potential: Modified Hormone Shown to Bind to Estrogen Receptor α	56
2.2.2	Examples of Estrogens Modified by Organometallics at the 11 β -Position	62
2.2.3	Targeting Prostate Cancer with Organometallic Androgens and Antiandrogens	64
2.2.4	Approach Toward Organometallic Radiopharmaceuticals	66
2.2.4.1	Steroidal Derivatives	66
2.2.4.2	Nonsteroidal Complexes	73
2.3	Epilog	75
	Acknowledgments	76
	References	76
3	Chirality in Organometallic Anticancer Complexes	85
	<i>Maria J. Romero and Peter J. Sadler</i>	
3.1	Introduction	85
3.2	Chirality in Arene Complexes	87
3.3	CIP System for the Nomenclature of Chiral-at-Metal Arene Complexes	89
3.4	Chiral Organometallic Complexes as Anticancer Agents	90
3.4.1	Chiral Carbene Complexes	90
3.4.2	Chiral Metallocene Complexes	91
3.4.3	Chiral Half-Sandwich Arene Complexes	93
3.4.4	Chirality at Metal in Supramolecular Complexes	97
3.5	Half-Sandwich Complexes with Chiral Metal Centers	99
3.5.1	Factors Influencing the Chirality at the Metal Center	100
3.5.1.1	Use of Chiral Ligands for Chiral Resolution at the Metal Center: Diastereoisomerism	100
3.5.1.2	CH- π Interactions: β -Phenyl Effect and Hydrogen Bond Interactions	101
3.5.1.3	Effect of the Temperature, Solvent and Ligands on the Metal Configuration	103

3.6	Conclusions	110
	Acknowledgments	111
	References	111
4	Gold Organometallics with Biological Properties	117
	<i>Maria Agostina Cinellu, Ingo Ott, and Angela Casini</i>	
4.1	Introduction: The Use of Gold in Medicine	117
4.2	Anticancer Gold Organometallics and Proposed Biological Targets	117
4.2.1	Cyclometalated Gold(III) Complexes with C,N-Donor Ligands	121
4.2.1.1	Types of Cycloaurated Complexes, Synthetic Methods, and Reactivity	122
4.2.1.2	Cycloaurated Complexes with Biological Activities	125
4.2.2	Gold N-Heterocyclic Carbene (NHC) Complexes	129
4.2.3	Gold Alkynyl Complexes	132
4.3	Conclusions and Perspectives	134
	List of Abbreviations	135
	References	135
5	On the Molecular Mechanisms of the Antimalarial Action of Ferroquine	141
	<i>Faustine Dubar and Christophe Biot</i>	
5.1	History and Development	141
5.2	Mechanism(s) of Action of 4-Aminoquinoline Antimalarials	141
5.3	Mechanism(s) of Action of Ferroquine as an Antimalarial	144
5.3.1	Antimalarial Activity	144
5.3.2	Metabolic Pathway of Ferroquine	144
5.3.3	Redox Properties of FQ	144
5.3.4	Basic Properties and Accumulation	147
5.3.5	Importance of Redox Properties of Ferrocene on Antimalarial Activity of FQ	155
5.3.6	Inhibition of Hemozoin Formation	157
5.4	Conclusion	160
	Acknowledgments	161
	List of Abbreviations	161
	References	161
6	Metal Carbonyl Prodrugs: CO Delivery and Beyond	165
	<i>Carlos C. Romão and Helena L.A. Vieira</i>	
6.1	Introducing CO in Biology	165
6.1.1	Origin	165
6.1.2	Biological Action and Targets of CO	166
6.1.3	Therapeutic Outlook	166
6.1.4	Measuring CO in Biology	167
6.2	Therapeutic Delivery of CO	167

6.2.1	CO Gas and Inhalation	167
6.2.2	Prodrugs for CO Delivery: CO-Releasing Molecules (CORM)	168
6.2.2.1	Definitions and Concept	168
6.2.3	Early CORMs	169
6.2.3.1	Nonmetal-Based CORMs	169
6.2.3.2	Metal Carbonyl-Based CORMs	169
6.2.4	The Chemical Biology of Early CORMs	171
6.2.4.1	[Ru(CO) ₃] ²⁺ -Based CORMs	171
6.2.4.2	[Mo(CO) _n]-Based CORMs	176
6.2.4.3	Miscellaneous Biologically Significant Observations on Early-Stage CORMs	177
6.3	Biological and Therapeutic Results Obtained with the Early-Stage CORMs	178
6.3.1	CORM and Inflammatory Response	178
6.3.2	Cardioprotective Effects of CORM	180
6.3.3	Central Nervous System and CORMs	180
6.3.4	Transplantation	181
6.3.5	Bactericide Effects of CORMs	181
6.3.6	CORMs: Tissue Regeneration and Modulation of Cell Proliferation/Differentiation	182
6.3.7	CORMs and Cancer Therapy?	182
6.4	Beyond the Early-Stage CORMs: Strategies for Finding New Candidates	183
6.4.1	Evaluation of CO Release from CORMs	184
6.4.2	Light Activated or photoCORMs	185
6.4.3	Chemically Activated CORMs	187
6.4.4	Bioactivated or Enzyme-Triggered CORMs (ET-CORMs)	191
6.5	Intracellular Detection of CORMs, Mechanistic Studies, and Other Unanswered Questions	192
6.6	Designing Pharmacologically Useful, Drug-like CORMs	193
6.6.1	The First Drug-like CORM	195
6.7	Final Remarks and Perspectives	196
	List of Abbreviations	196
	References	198
7	Dinitrosyl Iron Complexes with Natural Thiol-Containing Ligands: Physicochemistry, Biology, and Medicine	203
	<i>Anatoly F. Vanin</i>	
7.1	Introduction	203
7.2	The History of Detection and Identification of DNIC with Thiol-Containing Ligands in Microorganisms and Animal Tissues	204
7.3	Physicochemistry of DNIC with Natural Thiol-Containing Ligands	208

7.3.1	Mono- and Binuclear forms of DNIC with Natural Thiol-Containing Ligands	208
7.3.2	Two Approaches to the Synthesis of DNIC with Natural Thiol-Containing Ligands	209
7.3.3	Mechanisms of Formation of DNIC with Natural Thiol-Containing Ligands	210
7.3.4	The Electronic and Spatial Structures of DNIC with Thiol-Containing Ligands	212
7.3.5	DNIC with Thiol-Containing Ligands as NO and NO ⁺ Donors	213
7.4	Biological Effects of DNIC with Thiol-Containing Ligands	219
7.4.1	S-Nitrosating Effect of DNIC with Thiol-Containing Ligands	219
7.4.2	Vasodilator and Hypotensive Effects of DNIC with Thiol-Containing Ligands	220
7.4.3	Inhibiting Effect of DNIC with Thiol-Containing Ligands on Platelet Aggregation	224
7.4.4	DNIC with Thiol-Containing Ligands Increase Erythrocyte Elasticity	225
7.4.5	DNIC with Thiol-Containing Ligands Accelerate Skin Wound Healing in Animals	225
7.4.6	Erective Activity of DNIC	226
7.4.7	DNIC and Apoptosis	227
7.4.8	DNIC with Glutathione Inhibits the Development of Experimental Endometriosis in Rats	230
7.4.9	Other Examples of Biological Effects of DNIC with Thiol-Containing Ligands	232
7.5	DNIC with Thiol-Containing Ligands as a Basis in the Design of Drugs with a Broad Range of Therapeutic Activities	233
	List of Abbreviations	234
	Acknowledgments	235
	References	235

Part Two Metalloproteins, Catalysis, and Energy Production 239

8	The Bioorganometallic Chemistry of Hydrogenase	241
	<i>Ryan D. Bethel and Marcetta Y. Darensbourg</i>	
8.1	Introduction	241
8.1.1	Hydrogenase	241
8.1.2	The Chemistry of Hydrogen	243
8.1.3	Dihydrogen Metal Complexes	244
8.1.4	First Coordination Sphere Ligands	247
8.2	Structure and Function	247
8.2.1	The Active Sites of the Hydrogenases	247
8.2.1.1	[NiFe]- and [FeFe]-Hydrogenase	247
8.2.1.2	[Fe]-Hydrogenase	250

8.2.2	The Mechanisms of the Hydrogenases	251
8.3	Natural Biosynthesis and Synthetic Analogs of the Active Sites	253
8.3.1	Natural Biosynthesis of Hydrogenase Active Sites	253
8.3.1.1	Biosynthesis of [NiFe]-Hydrogenase	254
8.3.1.2	Biosynthesis of [FeFe]-Hydrogenase	255
8.3.2	Synthetic Analogs	256
8.3.2.1	Models of the [NiFe]-Hydrogenase Active Site	256
8.3.2.2	Models of the [FeFe]-Hydrogenase Active Site	259
8.3.2.3	Models of the [Fe]-Hydrogenase Active Site	263
8.4	Comments and Conclusion	265
	References	268

9 Bio-Organometallic Systems for the Hydrogen Economy: Engineering of Electrode Materials and Light-Driven Devices 273

Murielle Chavarot-Kerlidou, Pascale Chenevier, and Vincent Artero

9.1	Introduction	273
9.2	Electrode Materials for Hydrogen Evolution and Uptake	274
9.2.1	Electrode Materials-Based on Hydrogenases	274
9.2.2	Hydrogen Fuel Cell Electrodes Based on Hydrogenases	277
9.2.3	Electrode Materials Based on Bio-inspired Molecular Catalysts	279
9.2.3.1	Covalent Attachment of Catalyst to Electrode Material	279
9.2.3.2	Noncovalent Attachment of Catalyst to Electrode Material via π - π Stacking Interaction	283
9.3	Light-Driven Systems for Hydrogen Evolution	284
9.3.1	Biological and Biohybrid Systems	286
9.3.2	Bio-inspired Catalysis Approaches	288
9.3.2.1	Iron-Based Catalysts	289
9.3.2.2	Nickel-Based Catalysts	294
9.3.2.3	First Approaches toward Molecular-Based Photoelectrodes	295
9.4	Artificial Photosynthetic Systems	297
9.5	Summary and Conclusions	298
	List of Abbreviations	298
	References	299

10 Artificial Metalloenzymes Containing an Organometallic Active Site 305

Akira Onoda, Takashi Hayashi, and Michèle Salmain

10.1	Introduction	305
10.2	Dative Anchoring	306
10.2.1	Metalloproteins as Protein Hosts	306
10.2.2	Other Protein Hosts	313
10.3	Supramolecular Anchoring	316
10.3.1	(Strept)avidin as Protein Hosts	316
10.3.2	Antibodies as Protein Hosts	319
10.3.3	Other Protein Hosts	320

10.4	Covalent Anchoring	321
10.5	Mixed Anchoring Modes	326
10.5.1	Supramolecular + Covalent Anchoring	326
10.5.2	Supramolecular + Dative Anchoring	327
10.5.3	Dative + Covalent Anchoring	327
10.6	Peptide Scaffolds	328
10.7	Summary and Outlook	332
	List of Abbreviations	332
	References	333

Part Three Bioanalysis 339

11	Organometallic Bioprobes for Cellular Imaging	341
	<i>Emanuela Licandro, Monica Panigati, Michèle Salmain, and Anne Vessières</i>	
11.1	Introduction	341
11.1.1	Definition of Organometallic Bioprobes	342
11.1.2	Comparison of Different Imaging Techniques	343
11.2	Luminescence	346
11.2.1	Photophysical Properties of an Ideal Fluorophore for Cell Imaging	347
11.2.2	Emission Properties of the Main Classes of Organometallic Complexes	348
11.2.3	Other Advantages in the Use of Organometallic Complexes for Luminescence Imaging	351
11.2.4	Time-Resolved Techniques	352
11.2.5	Rhenium	352
11.2.5.1	Mononuclear Rhenium Complexes	352
11.2.5.2	Dinuclear Rhenium Complexes	360
11.2.5.3	Bimodal Rhenium Agents	362
11.2.6	Iridium	362
11.2.6.1	Simple Organometallic Iridium Complexes	362
11.2.6.2	Iridium Bioconjugates	365
11.2.7	Rhodium	367
11.2.7.1	Simple Organometallic Rhodium Complexes	367
11.2.7.2	Rhodium Bioconjugates	367
11.2.8	Platinum	368
11.2.8.1	Confocal Fluorescence Microscopy Imaging with Platinum Complexes with One or Two Photon Excitation	368
11.2.8.2	Time-Resolved Imaging with Platinum Complexes	370
11.2.9	Gold	371
11.2.9.1	Simple Organometallic Gold Complexes	371
11.2.9.2	Gold Bioconjugates	372
11.3	Vibrational Spectroscopy	372
11.3.1	Infrared Microscopy	374

11.3.2	Bimodal Detection (by Infrared and Luminescence)	377
11.3.3	AFM-IR Spectroscopy	378
11.3.4	Raman Spectromicroscopy	379
11.4	Miscellaneous	381
11.4.1	Nanoimaging Based on X-Ray Fluorescence	381
11.4.2	Ferrocene-Based Fluorescent Probe	382
11.5	Conclusions	383
	Acknowledgments	384
	Abbreviations	384
	References	386
	Index	393